Login
EN
Phones:
+7 (495) 482-41-18
+7 (495) 482-43-29

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

M.V. Zhuravleva

I.M. Sechenov First Moscow State Medical University (Sechenov University);
Scientific Centre of Medical Application Expertise of the Ministry of the Healthcare of the Russian Federation

P.R. Kamchatnov

Pirogov Russian National Research Medical University

N.S. Vasyukova

Federal Scientific Center-all-Russian Research Skriabin and Kovalenko Institute of Experimental Veterinary Medicine the Russian Academy of Sciences

V.V. Arkhipov

Scientific Center for Examination of Medical Devices

E.V. Kuznetsova

Research Institute for Healthcare and Medical Management

T.R. Kameneva

Konchalovsky City Clinical Hospital

S.Yu. Serebrova

Scientific Center for Examination of Medical Devices;
Sechenov First Moscow State Medical University

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11): 29–39

Results of clinical studies of the efficacy and safety of the use of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia

Authors:

M.V. Zhuravleva, P.R. Kamchatnov, N.S. Vasyukova, V.V. Arkhipov, E.V. Kuznetsova, T.R. Kameneva, S.Yu. Serebrova

More about the authors

DOI: 10.17116/jnevro202212211129

Read: 5969 times

Download PDF
Download PDF (RU)
Contact the author
Table of contents

Open to cite this article

Zhuravleva MV, Kamchatnov PR, Vasyukova NS, Arkhipov VV, Kuznetsova EV, Kameneva TR, Serebrova SYu. Results of clinical studies of the efficacy and safety of the use of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11):29‑39. (In Russ., In Engl.).
https://doi.org/10.17116/jnevro202212211129

Close metadata
Recommended articles:
Modern aspe­cts of diagnostic and therapeutic approaches in the mana­gement of patients with recu­rrent anogenital warts. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(5):658-665
Current aspe­cts of the rela­tionship between depression and cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):66-74
Improving the quality of life and the possibility of pathogenetic therapy in adult patients with cere­bral palsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):75-84
Perceptions of the disease and self-assessment of the quality of life in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):24-31
Higher-level ambu­lation diso­rders in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):32-38
Cognitive dysfunction in children with nervous system diseases: modern approaches to diagnosis and treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):69-79
Modern treatment of patients with cervical cancer. Russian Bulletin of Obstetrician-Gynecologist. 2025;(6):29-36
Audi­tory dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):11-18
Features of arte­rial hype­rtension in indi­viduals with anxiety diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):44-51
Brain aging: mole­cular targets of gero­protection and prevention stra­tegies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):132-139

Chronic cerebral ischemia (CCI) is a common syndrome that, in the absence of adequate therapy, is characterized by a progressive course, an increase in cognitive, emotional, motor and other disorders, eventually leading to persistent disability of the patient. In the treatment of patients with CCI, the use of drugs with a multimodal neuroprotective effect is indicated. The results of the analysis of a series of clinical trials of the drugs Mexidol and Mexidol FORTE in patients with CCI are presented. The effects in relation to cognitive, emotional, asthenic, vegetative and other manifestations of CCI are considered. It is concluded that it is advisable to consistently use the drugs Mexidol and Mexidol FORTE in such patients.

Keywords:

chronic cerebral ischemia
cognitive impairment
Mexidol
emotional disorders
treatment

Authors:

M.V. Zhuravleva

I.M. Sechenov First Moscow State Medical University (Sechenov University);
Scientific Centre of Medical Application Expertise of the Ministry of the Healthcare of the Russian Federation

P.R. Kamchatnov

Pirogov Russian National Research Medical University

N.S. Vasyukova

Federal Scientific Center-all-Russian Research Skriabin and Kovalenko Institute of Experimental Veterinary Medicine the Russian Academy of Sciences

V.V. Arkhipov

Scientific Center for Examination of Medical Devices

E.V. Kuznetsova

Research Institute for Healthcare and Medical Management

T.R. Kameneva

Konchalovsky City Clinical Hospital

S.Yu. Serebrova

Scientific Center for Examination of Medical Devices;
Sechenov First Moscow State Medical University

Received:

26.09.2022

Accepted:

24.10.2022

List of references:

  1. Wardlaw JM, Smith EE, Biessels GJ, et al. STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838.  https://doi.org/10.1016/S1474-4422(13)70124-8
  2. Kulesh AA, Emelin AYu, Bogolepova AN, et al. Clinical manifestations and diagnostic issues of chronic cerebrovascular disease (chronic cerebral ischemia) at an early (pre-dement) stage. Nevrologiya, Nejropsihiatriya, Psihosomatika. 2021;13(1):4-12. (In Russ.). https://doi.org/10.14412/2074-2711-2021-1-4-12
  3. Haag MD, Hofman A, Koudstaal PJ, et al. Duration of antihypertensive drug use and risk of dementia: a prospective cohort study. Neurology. 2009;72(20):1727-1234. https://doi.org/10.1212/01.wnl.0000345062.86148.3f
  4. Diener HC, Sacco RL, Yusuf S, et al. Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7(10):875-884.  https://doi.org/10.1016/S1474-4422(08)70198-4
  5. Reznik EV, Dzhioeva ON, Nikitin IG. Secondary prevention of stroke: the view of a therapist and cardiologist. Consilium Medicum. Neurology and Rheumatology. 2019;1:12-24. (In Russ.).
  6. Belova AN, Bogdanov EI, Voznyuk IA, et al. Therapy of moderate cognitive impairment in the early recovery period of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(5):1-7. (In Russ.). https://doi.org/10.17116/jnevro202112105133
  7. Pyshkina LI, Abieva AR, Yasamanova AN, et al. The Course of cerebrovascular pathology in patients with carotid artery stenosis. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;9(2):24-29. (In Russ.). https://doi.org/10.17116/jnevro20181180928
  8. Khripun AI, Salikov AV, Mironkov AB, et al. Results of endovascular treatment of acute tandem occlusion of the internal carotid and middle cerebral arteries. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(12-2):5-10. (In Russ.). https://doi.org/10.17116/jnevro20201201225
  9. Voronina TA. Antioxidants/antihypoxants: the missing puzzle piece in effective pathogenetic therapy for COVID-19. Infekc Bolezni. 2020;18(2):97-102. (In Russ.). https://doi.org/10.20953/1729-9225-2020-2-97-102
  10. Schulkin AV, Filimonova AA. Role of free radical oxidation, hypoxia and their correction in COVID-19 pathogenesis. Therapy. 2020;45(5):187-194. (In Russ.). https://doi.org/10.18565/therapy.2020.5.187-194
  11. Voronina TA. Mexidol: main neuropsychotropic effects and mechanisms of action. Farmateka. 2009;180(6):1-4. (In Russ.).
  12. Voronina TA. Pioner antioksidantnoy neyroprotektsii. 20 let v klinicheskoy praktike. Rossiyskiy Meditsinskiy Zhurnal. Nevrologiya. 2016;7:434-438. (In Russ.).
  13. Kraineva VA. The experimental study of peculiarities and mechanism of neuroprotective action of mexidol in hemorrhagic stroke. Bulletin of Experimental Biology and Medicine.2006;12(1):40-44. (In Russ.).
  14. Kirova YuI, Shakova FM, Germanova EL, et al. The effect of Mexidol on cerebral mitochondriogenesis at a young age and during aging. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(1):55-61. (In Russ.). https://doi.org/10.17116/jnevro202012001162
  15. Shalashova ML, Dudaeva NG, Golovacheva TV. The use of Mexidol in combination therapy with traditional antihypertensive agents in patients with arterial hypertension with signs of chronic cerebral vascular insufficiency. Bulletin of Experimental Biology and Medicine. 2006;1(7):152-155. (In Russ.).
  16. Semchenko LN, Drozdova TV, Zinovieva MN. The use of the drug Mexidol for the treatment of patients with chronic cerebrovascular insufficiency with vestibulocochlear manifestations. Bulletin of Experimental Biology and Medicine. 2006;1(5):75-79. (In Russ.).
  17. Shetekauri SA. Modern possibilities of antioxidant therapy and experience of Mexidol treatment in patients with chronic cerebrovascular insufficiency. Bulletin of Experimental Biology and Medicine. 2006;1(4):156-158. (In Russ.).
  18. Duma SN. Treatment of vertigo in elderly patients with chronic cerebrovascular pathology. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):55-59. (In Russ.). https://doi.org/10.14412/2074-2711-2018-1-55-59
  19. Bolotova EV, Lushpai TYu, Kovrigina IV. Improving the effectiveness of treatment of hypertensive encephalopathy with mexidol. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(4):61-64. (In Russ.). https://doi.org/10.17116/jnevro20181184161-64
  20. Chukanova EI, Chukanova AS. Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;119(9):39-45. (In Russ.). https://doi.org/10.17116/jnevro201911909139
  21. Antipenko EA, Deryugina AV, Gustov AV. Systemic stress-limiting effect of mexidol in chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(4):28-31. (In Russ.). https://doi.org/10.17116/jnevro2016116412-6
  22. Tanashyan MM, Lagoda OV, Antonova KV. Chronic cerebrovascular diseases on the background of metabolic syndrome: new approaches to treatment. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(11):21-26. (In Russ.).
  23. Fedin AI, Zakharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
  24. Yanishevsky SN. Experience of using the drug Mexidol in the treatment of chronic cerebral circulatory insufficiency in patients with stenosing-occlusive lesions of the main brachycephalic vessels. Bulletin of Experimental Biology and Medicine. 2006;5(1):159-163. (In Russ.).
  25. Abramenko YuV. Evaluation of clinical efficacy, vasoactive and metabolic effects of exidol in elderly patients with dyscirculatory encephalopathy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2011;111(11):35-41. (In Russ.).
  26. Chukanova EI, Chukanova AS, Mamaeva HI. Results of a study of the efficacy and safety of exidol in patients with chronic cerebral ischemia. Zhurnal Nevrologii I Psikhiatrii im. S.S. Korsakova. 2015;115(2):71-74. (In Russ.).
  27. Shchepankevich LA, Nikolaev YuA, Taneeva EV, et al. The efficacy and safety study of Mexidol and Mexidol FORTE 250 in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(10):32-37. (In Russ.). https://doi.org/10.17116/jnevro202112110132
  28. Karpikova NI, Peteryukhina AA. The use of the drug Mexidol for the treatment of patients with diseases of the cerebral vessels. Bulletin of Experimental Biology and Medicine. 2006;6(1):32-33. (In Russ.).
  29. Smirnova IN, Fedorova TN, Tanashyan MM, Suslina ZA. Clinical efficacy and antioxidant activity of Mexidol in chronic cerebrovascular diseases. Nervous Diseases. 2006;12(1):33-36. (In Russ.).
Contact the author
Email
Message

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
E-mail
Password
Forgot Password?

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.